Pemetrexed Formulations
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 16/297,125, filed Mar 8, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,793,813 | Pemetrexed Formulations In force · Low confidence | Eagle Pharmaceuticals, Inc. | In force | Low confidence | ||
| US 12,115,164 | Pemetrexed Formulations In force · Medium confidence | Eagle Pharmaceuticals, Inc. | In force | Medium confidence | ||
| Application 15/048,416 | Pemetrexed Formulations Abandoned Abandoned Dec 11, 2017 | Eagle Pharmaceuticals, Inc. | Abandoned | Abandoned Dec 11, 2017 | ||
| Application 15/828,858 | Pemetrexed Formulations Abandoned Abandoned Apr 25, 2019 | Eagle Pharmaceuticals, Inc. | Abandoned | Abandoned Apr 25, 2019 | ||
| Application 16/297,125 | Pemetrexed Formulations Abandoned Abandoned Apr 2, 2024 | Eagle Pharmaceuticals, Inc. | Abandoned | Abandoned Apr 2, 2024 | ||
| Application 17/898,558 | Pemetrexed Formulations Abandoned Abandoned Oct 20, 2023 | Eagle Pharmaceuticals, Inc. | Abandoned | Abandoned Oct 20, 2023 | ||
| Application 17/898,637 | Pemetrexed Formulations Abandoned Abandoned Nov 20, 2023 | Eagle Pharmaceuticals, Inc. | Abandoned | Abandoned Nov 20, 2023 | ||
| Application 17/898,984 | Pemetrexed Formulations Abandoned Abandoned Oct 20, 2023 | Eagle Pharmaceuticals, Inc. | Abandoned | Abandoned Oct 20, 2023 | ||
| Application 18/236,480 | Pemetrexed Formulations Abandoned Abandoned Oct 31, 2023 | Eagle Pharmaceuticals, Inc. | Abandoned | Abandoned Oct 31, 2023 | ||
| Application 18/456,772 | Pemetrexed Formulations Pending Not granted | Eagle Pharmaceuticals, Inc. | Pending | Not granted | ||
| 1 more patent in this group · Pro | ||||||
10 of 11 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 11.
2 of these are in force and held by Eagle Pharmaceuticals, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.